

MH
5-3-00
#2

PATENT
Docket No. 395/35

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor : Gerard M. HOUSEY
Serial No. : Unassigned
Filing Date : Unassigned
For: METHOD FOR SCREENING FOR PROTEIN
INHIBITORS AND ACTIVATORS
Examiner : Unassigned
Art Unit : Unassigned

Assistant Commissioner for Patents
Washington D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to examination, please amend the above application for patent as follows.

Please cancel claims 1-30, and add the following claims:

- Insert At*
31. A pharmaceutical composition for treating a disease or other condition for which therapeutic treatment could be beneficial, which comprises a therapeutically effective amount of an inhibitor or activator of a protein which was characterized as an inhibitor or activator of the protein at least in part through a process comprising the steps of:
- (a) selecting a substance, which had not been previously administered as a treatment for the disease or other condition;
- Conclude*

*All
conclude*

- (b) providing a test cell in which the protein is present at a higher level relative to a control cell which produces the protein at a lower level or essentially does not produce the protein, and wherein production of the protein in the test cell evokes a responsive change in a phenotypic characteristic, other than the level of the protein in the cell, per se, which is comparatively greater than in the control cell;
- (c) treating the test cell containing the protein with the substance; and
- (d) examining the treated test cell to determine whether it exhibits a change in the phenotypic characteristic in response to the substance.

32. A substance which is an inhibitor or activator of a protein, the protein being functionally related to a disease or other condition for which therapeutic treatment could be beneficial, which was characterized as an inhibitor or activator of the protein at least in part through a process comprising the steps of:

- (a) selecting a substance which had not been previously administered for treatment of the disease or other condition;
- (b) providing a test cell in which the protein is present at a higher level relative to a control cell which produces the protein at a lower level or essentially does not produce the protein, and wherein production of the protein in the test cell evokes a responsive change in a phenotypic characteristic, other than the level of the protein in the cell, per se, which is comparatively greater than in the control cell;
- (c) treating the test cell containing the protein with the substance; and